Chorea: Clinical Trials

6 trials for Chorea, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 terminated. 6 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Terminated 6
Phase 24Terminated 4

Follow Chorea: new trials by email Literature Review of Chorea trials Research Report on Chorea

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HD
Deutetrabenazine Oral Tablet [Austedo], Placebo oral tablet - Huntington Disease
Phase 1TerminatedFundacion Huntington Puerto Rico362022-01-212025-02-27
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
WVE-120101 - Huntington Disease
Phase 1 / Phase 2TerminatedWave Life Sciences USA, Inc.272020-04-132022-02-09
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
WVE-120102 - Huntington Disease
Phase 1 / Phase 2TerminatedWave Life Sciences USA, Inc.362019-09-242022-02-09
Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
WVE-120101, Placebo - Huntington's Disease
Phase 1 / Phase 2TerminatedWave Life Sciences USA, Inc.612017-07-172022-02-10
Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
WVE-120102, Placebo - Huntington's Disease
Phase 1 / Phase 2TerminatedWave Life Sciences USA, Inc.882017-07-172022-04-25
Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers
PBF-999 / 160 mg, PBF-999 / 320 mg, Placebo - Huntington Disease
Phase 1TerminatedPalobiofarma SL82016-03-012016-09-20

Narrower conditions

Huntington Disease (6)  ·  Mental Disorders (1)

Broader conditions

Basal Ganglia Diseases (6)  ·  Brain Diseases (6)  ·  Central Nervous System Diseases (6)  ·  Cognition Disorders (6)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6)  ·  Dementia (6)  ·  Dyskinesias (6)  ·  Genetic Diseases, Inborn (6)  ·  Heredodegenerative Disorders, Nervous System (6)  ·  Movement Disorders (6)  ·  Nervous System Diseases (6)  ·  Neurocognitive Disorders (6)  ·  Neurodegenerative Diseases (6)  ·  Mental Disorders (5)

Interventions

deutetrabenazine (1)

Sponsors

Wave Life Sciences USA, Inc. (4)  ·  Fundacion Huntington Puerto Rico (1)  ·  Palobiofarma SL (1)

Countries

Australia (4)  ·  Canada (4)  ·  Denmark (4)  ·  France (4)  ·  Germany (4)  ·  Poland (4)  ·  United Kingdom (4)  ·  Puerto Rico (1)  ·  Spain (1)  ·  United States (1)

Top investigators

Joan Martinez, MD (1)

Results publications

PMID 29480210, PMID 32250312

NIH funding

2015 (1)